Ipca Labs Q1FY27: Revenue up 21%, Net Profit jumps 42% standalone, 80% consolidated

Revenue growth above 20%Profit growth above 25%EBITDA margin expansionResults View source PDF Explain this filing

IPCALAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.4%Reaction day

₹1770.00

prior close

₹1842.00

announcement price

In-mkt

timing

Nifty Midcap 150market+0.1%+1.3% vs market

Pharmaceuticals peers, median of 166sector+0.1%+1.3% vs sector

On the reaction day the stock moved 1.3 pts more than Nifty Midcap 150 and 1.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.5

10m

-0.1

15m

-1.4

30m

-1.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.4+0.1+1.3+0.1+1.3

Next day

-2.1-0.4-1.7-0.2-1.9

+5.9-0.3+6.2-0.2+6.1

+6.1-0.7+6.8-0.4+6.5

+7.7-0.9+8.6-1.5+9.1

+7.3-0.6+7.9-0.9+8.2

+8.5-0.4+8.9-0.6+9.1

15d

+10.8-1.3+12.1+0.3+10.5

+9.5-4.9+14.5-0.2+9.7

+7.7-7.2+14.9-2.4+10.1

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Ipca Labs Q1FY27: Standalone revenue rose 21% to Rs 2,119 crores, net profit up 42% at Rs 373 crores. Consolidated revenue up 21% to Rs 2,309 crores, net profit up 80% at Rs 423 crores. EBITDA margins expanded - standalone 26.27% (vs 23.82%) and consolidated 22.88% (vs 18.39%). Exports grew 34% to Rs 935 crores. Domestic formulations up 13% at Rs 1,082 crores. Auditors gave unmodified review reports. Board approved amalgamation of Krebs Biochemicals.

Likely market impact

Strong beat on revenue, margins, and profits. Export momentum and margin expansion point to a positive earnings trajectory for shareholders.